Pacific BioLabs clients are on the cutting edge of developing novel therapeutic approaches to target unmet medical needs. Nine Continents Medical, Inc., recently acquired by Coloplast a global medical device company in intimate healthcare, has focused on the development of innovative therapeutic solutions for the treatment of overactive bladder (OAB). Their device, a tibial nerve stimulator implanted into the lower leg requires no activation, recharging or recurring doctor visits. Pivotal studies in 2021 are aimed to demonstrate the utility of this device in hopes of providing patients with an additional option in reducing/eliminating symptomology of OAB. Pacific BioLabs has worked closely with Nine Continents supporting the company’s efforts evaluating the biocompatibility, chronic systemic toxicity, bioburden, and bacterial endotoxin status of the nerve stimulator device.
According to Peter Jacobson, Nine Continents CEO and Co-Founder, “A clinical feasibility study for the neurostimulator for overactive bladder we tested at PBL was successfully completed, and we look forward to the pivotal study”.
PBL is delighted to have collaborated with Nine Continents and will continue to strive as the Service Leader in Life Science Testing for all our clients.